Pilot study testing varenicline combined with a behavioral intervention for promoting smoking cessation and pain management among patients with cancer.

Authors

Kathryn I Pollak, James M Davis, Laura J Fish, Linda M Sutton, Maren K Olsen, Lynda Owen, Sarah Hantzmon, Brianna Richardson, Aviel Alkon, Tamara J Somers

Published in

Journal of cancer survivorship : research and practice. Nov 01, 2026. Epub Nov 01, 2026.

Abstract

Many patients with cancer smoke and also experience pain. Smoking offers short-term pain relief but exacerbates pain long-term. We pilot tested the feasibility, acceptability, and preliminary efficacy of adding varenicline to a combined behavioral treatment that addresses smoking cessation and pain management.
We conducted a single-arm pilot study in which we provided varenicline paired with a 4-session behavioral treatment that uses the same techniques to help people quit smoking and manage their pain. Our primary outcome was 7-day point prevalence abstinence at 6-months post-randomization.
We recruited 19 patients with cancer. 80% of the patients who received the intervention rated it as "helpful" (4 or 5 out of 5) in helping them quit smoking; 60% rated it as helpful in managing their pain. Further, 94% would recommend the program to other patients with cancer. Roughly one-third (35%) (6/17) reported biochemically validated abstinence at 6 months post-randomization. We did not see improvements in reported pain but did see improvements in pain self-efficacy.
Our pilot data suggest the feasibility, acceptability, and preliminary efficacy of this approach for promoting cessation. We need to refine aspects to help address pain, yet addressing pain in addition to smoking cessation might motivate more patients with cancer to join the program. The next step is to conduct a large randomized controlled trial to fully test the efficacy of the combined behavioral program with varenicline.
A combined smoking cessation and pain program paired with varenicline might help patients with cancer quit smoking.
NCT06029907.

PMID:
42967265
Bibliographic data and abstract were imported from PubMed on 01 Nov 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.